ReNeuron Group plc Total Voting Rights (1150X)
May 04 2021 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 1150X
ReNeuron Group plc
04 May 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Total Voting Rights
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that at 30 April
2021, the Company had 56,863,705 ordinary shares in issue, each
carrying one voting right. This follows the issue of 8,000 new
shares arising from the exercise of options by staff, such shares
having been admitted under the Company's existing block listing
arrangement.
As the Company holds no ordinary shares in treasury, the figure
of 56,863,705 may be used by shareholders as the denominator for
the calculation by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Michael Hunt, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker)
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking) +44 (0)20 3328 5656
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRZZGZDFLFGMZM
(END) Dow Jones Newswires
May 04, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024